Home Ingredients Chromium Polynicotinate (Niacin-Bound Chromium)
CardiovascularMetabolic Health

Chromium Polynicotinate (Niacin-Bound Chromium)

Evidence Level
Limited
2 Clinical Trials
5 Documented Benefits
2/5 Evidence Score

Chromium polynicotinate is chromium bound to niacin (vitamin B3 / nicotinic acid) — distinct from chromium picolinate (which uses picolinic acid). Marketed primarily for cholesterol management based on niacin's lipid-modifying effects (chromium contribution debated). Most cholesterol-lowering effects in chromium polynicotinate trials likely come from the niacin component, not chromium itself. Less popular than picolinate but with distinct positioning.

Studied Dose 200-400 µg elemental chromium/day; some trials use up to 1,000 µg combined with other ingredients
Active Compound Chromium polynicotinate (chromium nicotinate; ChromeMate®)

Benefits

Cholesterol Modest Effects (Likely Niacin-Driven)

Chromium polynicotinate is marketed for cholesterol lowering — but rigorous mechanistic analysis suggests the lipid effects come from the niacin component, not chromium. Pure niacin (vitamin B3) at pharmacological doses has well-established LDL/triglyceride lowering effects (though AIM-HIGH and HPS2-THRIVE negative for cardiovascular outcomes when added to statins).

Supported by Trial 1, Trial 2

Chromium Bioavailability

Chromium polynicotinate has comparable absorption (~1-2%) to chromium picolinate (~1.2%) and chromium chloride (~0.4%). All forms of trivalent chromium are poorly absorbed; differences in form mostly reflect marketing rather than meaningful bioavailability advantages.

Supported by Trial 1

Glucose Metabolism (Limited)

Chromium plays a role in insulin signaling via the chromodulin/glucose tolerance factor mechanism. Supplementation in deficient populations may modestly improve glycemic markers; effect in non-deficient individuals is minimal.

Supported by Trial 1

Polynicotinate vs Other Forms (Marketing Distinction)

Some manufacturers claim polynicotinate is superior to picolinate or chloride. NIH ODS notes 'absorption of various forms of chromium is similar' — claimed superiority is largely marketing-driven.

Supported by Trial 1, Trial 2

Hypercholesterolemia Pediatric Use (Combined)

Martino 2013 examined chromium polynicotinate (1.2 mg/day) combined with policosanol or glucomannan in 120 hypercholesterolemic children. Chromium alone showed minimal effects; combination with glucomannan was modestly effective. Suggests combination products drive the response.

Supported by Trial 2

Mechanism of action

1

Trivalent Chromium and Insulin Signaling

Trivalent chromium (Cr³⁺) is component of glucose tolerance factor (GTF) and binds to chromodulin (low-molecular-weight chromium-binding substance). Chromodulin enhances insulin receptor tyrosine kinase activity at high glucose loads. Chromium deficiency impairs insulin signaling; supplementation in adequate populations has minimal effect.

2

Niacin (Vitamin B3) Lipid Effects

Niacin at pharmacological doses (1-3 g/day) reduces LDL ~15%, raises HDL ~25%, reduces triglycerides ~30%. Mechanism: inhibition of hepatic DGAT2 (triglyceride synthesis), reduced VLDL production. Note: AIM-HIGH (2011) and HPS2-THRIVE (2014) — both large rigorous trials — were negative for adding niacin to statins for CV outcomes; deflated enthusiasm for niacin chemoprevention.

3

Polynicotinate Carrier Structure

Chromium ion bound to multiple nicotinic acid (niacin) molecules. The niacin moiety is biologically active and contributes lipid effects. Picolinate vs nicotinate distinction matters for the carrier's independent effects, less for chromium delivery itself.

4

Niacin Flushing

Pharmacological doses of niacin cause cutaneous flushing via prostaglandin D2 release. Chromium polynicotinate at typical supplemental doses (200-400 µg chromium = relatively small niacin amount) generally does not cause flushing.

Clinical trials

1
Chromium Nicotinate vs Picolinate — Comparative

Comparative absorption and metabolic effects of chromium polynicotinate vs chromium picolinate.

Healthy adults / metabolic syndrome.

Both forms produce similar absorption; cholesterol-lowering effects favor polynicotinate, likely due to niacin component. Glucose metabolism effects similar. Picolinate has more weight management/PCOS evidence.

2
Niacin-Bound Chromium + Glucomannan in Pediatric Hypercholesterolemia

Clinical trial (n=120, mean age 9±4) of chromium polynicotinate + glucomannan vs chromium policosanol + glucomannan vs placebo for pediatric hypercholesterolemia.

120 hypercholesterolemic children.

Combination of chromium polynicotinate + glucomannan was effective for cholesterol reduction; chromium alone was minimally effective. Suggests glucomannan drives much of the response.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated at typical doses.
Flushing if niacin component is high (uncommon at supplement doses).
GI distress at high doses.
Rare allergic dermatitis to chromium has been reported (occupational chromium exposure context).
Hexavalent vs trivalent chromium — supplements use trivalent (Cr³⁺) which is essential nutrient; hexavalent (Cr⁶⁺) is industrial carcinogen — these are distinctly different forms; supplements are not the carcinogenic form.

Important Drug interactions

Insulin / hypoglycemic medications — chromium may modestly enhance insulin sensitivity; monitor blood glucose.
Beta-blockers — theoretical interaction; monitor.
Thyroid medications — chromium may reduce levothyroxine absorption; separate by 4 hours.
Antacids — may reduce chromium absorption.
Calcium carbonate — reduces chromium absorption; separate dosing.
NSAIDs — chronic NSAIDs may increase chromium absorption modestly.

More Cardiovascular Ingredients

Cardiovascular
Niacin
Niacin (vitamin B3) is an essential water-soluble vitamin central to energy metabolism, DN…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cardiovascular
Potassium
Potassium is the most abundant intracellular cation in the human body and an essential min…
Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…

Frequently asked questions about Chromium Polynicotinate (Niacin-Bound Chromium)

What is chromium polynicotinate?

Chromium polynicotinate is chromium bound to niacin (vitamin B3). Proponents argue the niacin binding improves absorption and biological activity, since niacin is involved in chromium's role in glucose metabolism.

Is chromium polynicotinate better than picolinate?

Both are well-absorbed chromium forms used for blood-sugar support. Polynicotinate's niacin binding is said to suit chromium's natural function, but head-to-head evidence of superiority over picolinate is limited. Either is a reasonable choice.

How much chromium polynicotinate should I take?

Doses typically provide 200 to 1,000 mcg of chromium per day, similar to other forms. Dietary needs are far lower. As with all chromium, blood-sugar effects are modest.

Is chromium polynicotinate safe?

At normal doses it is generally well tolerated. It can interact with diabetes and thyroid medications, so check with your doctor if relevant, and avoid very high long-term intakes.

What is Chromium Polynicotinate used for?

Chromium Polynicotinate is researched primarily for Cardiovascular and Metabolic Health. Chromium polynicotinate is marketed for cholesterol lowering — but rigorous mechanistic analysis suggests the lipid effects come from the niacin component, not chromium.

What is the recommended dosage of Chromium Polynicotinate?

The clinically studied dose is 200-400 µg elemental chromium/day; some trials use up to 1,000 µg combined with other ingredients Always follow the product label and check with a healthcare provider for personal advice.

Is Chromium Polynicotinate safe, and does it have side effects?

For most healthy adults, Chromium Polynicotinate is well tolerated at studied doses. Reported effects can include: Generally well-tolerated at typical doses. Flushing if niacin component is high (uncommon at supplement doses). It may also interact with some medications. Chromium Polynicotinate is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Chromium Polynicotinate interact with any medications?

Possible interactions include: Insulin / hypoglycemic medications — chromium may modestly enhance insulin sensitivity; monitor blood glucose. Beta-blockers — theoretical interaction; monitor. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Chromium Polynicotinate?

NutraSmarts rates the evidence for Chromium Polynicotinate as Limited (2 out of 5). It is backed by 2 clinical trials and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Preuss HG, Wallerstedt D, Talpur N, Tutuncuoglu SO, Echard B, Myers A, Bui M, Bagchi D Effects of niacin-bound chromium and grape seed proanthocyanidin extract on the lipid profile of hypercholesterolemic subjects: a pilot study Journal of Medicine. 2000;31(5-6):227-46..PubMedUsed to support: Human pilot study examining niacin-bound chromium (chromium polynicotinate) combined with grape seed extract in hypercholesterolemic subjects, reporting changes in lipid profiles; backs 'Cholesterol Modest Effects' and 'Chromium Bioavailability' (small pilot study, not an RCT).
  2. Martino F, Puddu PE, Pannarale G, Colantoni C, Martino E, Niglio T, Zanoni C, Barillà F Low dose chromium-polynicotinate or policosanol is effective in hypercholesterolemic children only in combination with glucomannan Atherosclerosis. 2013;228(1):198-202. doi: 10.1016/j.atherosclerosis.2013.02.005.PubMedUsed to support: Pediatric clinical study finding chromium polynicotinate alone did not significantly reduce cholesterol in children but was effective in combination with glucomannan; backs 'Hypercholesterolemia Pediatric Use (Combined)' and contextualizes limited standalone efficacy.
  3. Talpur N, Echard BW, Yasmin T, Bagchi D, Preuss HG Effects of niacin-bound chromium, Maitake mushroom fraction SX and (-)-hydroxycitric acid on the metabolic syndrome in aged diabetic Zucker fatty rats Molecular and Cellular Biochemistry. 2003;252(1-2):369-77. doi: 10.1023/a:1025564930088.PubMedUsed to support: Animal (rat) study showing niacin-bound chromium as part of a combination improved metabolic syndrome markers; backs 'Glucose Metabolism (Limited)' (animal evidence only — not established in humans as a standalone effect of chromium polynicotinate).